Tech Company Financing Transactions
Cardurion Pharma Funding Round
Ascenta Capital, Bain Capital Life Sciences and Bain Capital Private Equity participated in a $260 million Series B capital raise for Cardurion Pharma. The round was announced by the company on 7/16/2024.
Transaction Overview
Company Name
Announced On
7/16/2024
Transaction Type
Venture Equity
Amount
$260,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to conduct later-stage clinical trials with its two lead drug candidates, a first-in-class phosphodiesterase-9 (PDE9) inhibitor for heart failure and the first clinical-stage Calcium/Calmodulin-dependent Protein Kinase II (CaMKII) inhibitor with broad therapeutic potential. In addition, the funding will be used to expand the cardiovascular indications for Cardurion's portfolio of drug candidates, to progress internal discovery programs and to acquire additional therapeutic assets targeting unmet needs in the cardiovascular disease area.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Lincoln St. 30th Floor
Boston, MA 02111
USA
Boston, MA 02111
USA
Phone
Website
Email Address
Overview
Cardiovascular disease is the leading cause of death worldwide in both men and women, accounting for over 17 million deaths per year, and often striking in the prime of life. This number is expected to grow to nearly 24 million by 2030.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 7/16/2024: Asceneuron venture capital transaction
Next: 7/16/2024: Making Space venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs